Alleviant ALLAY-HF Study

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 700 participants.

Also called NCT05685303

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 700 participants (planned count) (from the registry)
Sponsor
Alleviant Medical, Inc. (from the registry)
Registry
  • NCT NCT05685303
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Australia, Austria, Belgium, Bulgaria, Canada, Czechia, Georgia, Germany, Israel, Italy, New Zealand, Poland, Spain (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05685303. Randomized; double masking; primary purpose treatment. Start 2023-01-10 (actual); primary completion 2027-12-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Alleviant ALLAY-HF Study
Condition
Heart Failure
Intervention (Device)
Alleviant ALV1 System
Intervention (Other)
Sham-Control
Lead sponsor
Alleviant Medical, Inc. (class: industry)

Record details

Record id
cardio:ct-nct05685303
Content hash
7bb91d6042987a463c20cb8fd07bac5305ff7b1436a0eeb91f54c5e42273f0c3